21 CFR 516.26
§ 516.26 Amendment to MUMS-drug designation.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 516.26, § 516.26 Amendment to MUMS-drug designation, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/87008
- Permanent ID
ys:prov:87008@1- SHA-256
9cbf33c440c0e2b752617a6904826fbf759f5b36644ebee5bbb7e87cf76f3ccb
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) At any time prior to conditional approval or approval of an application for a MUMS-designated drug, the sponsor may apply for an amendment to the designated intended use if the proposed change is due to new and unexpected findings in research on the drug, information arising from FDA recommendations, or other unforeseen developments.
(b) FDA will grant the amendment if it finds:
(1) That the initial designation request was made in good faith;
(2) That the amendment is intended to make the MUMS-drug designated intended use conform to the results of new and unexpected findings in research on the drug, information arising from FDA recommendations, or other unforeseen developments; and
(3) In the case of a minor use, that as of the date of the submission of the amendment request, the amendment would not result in the intended use of the drug no longer being considered a minor use.
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.